PD-1 blockade improves Kupffer cell bacterial clearance in acute liver injury.
Acetaminophen
/ adverse effects
Adult
Animals
Bacteria
/ immunology
Bacterial Infections
/ drug therapy
Chemical and Drug Induced Liver Injury
/ drug therapy
Female
Humans
Immune Checkpoint Inhibitors
/ pharmacology
Kupffer Cells
/ immunology
Male
Mice
Mice, Knockout
Middle Aged
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Hepatology
Immunology
Innate immunity
Macrophages
Journal
The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877
Informations de publication
Date de publication:
15 02 2021
15 02 2021
Historique:
received:
13
05
2020
accepted:
10
12
2020
pubmed:
16
12
2020
medline:
21
9
2021
entrez:
15
12
2020
Statut:
ppublish
Résumé
Patients with acute liver failure (ALF) have systemic innate immune suppression and increased susceptibility to infections. Programmed cell death 1 (PD-1) expression by macrophages has been associated with immune suppression during sepsis and cancer. We therefore examined the role of the programmed cell death 1/programmed death ligand 1 (PD-1/PD-L1) pathway in regulating Kupffer cell (KC) inflammatory and antimicrobial responses in acetaminophen-induced (APAP-induced) acute liver injury. Using intravital imaging and flow cytometry, we found impaired KC bacterial clearance and systemic bacterial dissemination in mice with liver injury. We detected increased PD-1 and PD-L1 expression in KCs and lymphocyte subsets, respectively, during injury resolution. Gene expression profiling of PD-1+ KCs revealed an immune-suppressive profile and reduced pathogen responses. Compared with WT mice, PD-1-deficient mice and anti-PD-1-treated mice with liver injury showed improved KC bacterial clearance, a reduced tissue bacterial load, and protection from sepsis. Blood samples from patients with ALF revealed enhanced PD-1 and PD-L1 expression by monocytes and lymphocytes, respectively, and that soluble PD-L1 plasma levels could predict outcomes and sepsis. PD-1 in vitro blockade restored monocyte functionality. Our study describes a role for the PD-1/PD-L1 axis in suppressing KC and monocyte antimicrobial responses after liver injury and identifies anti-PD-1 immunotherapy as a strategy to reduce infection susceptibility in ALF.
Identifiants
pubmed: 33320839
pii: 140196
doi: 10.1172/JCI140196
pmc: PMC7880414
doi:
pii:
Substances chimiques
Immune Checkpoint Inhibitors
0
PDCD1 protein, human
0
Pdcd1 protein, mouse
0
Programmed Cell Death 1 Receptor
0
Acetaminophen
362O9ITL9D
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medical Research Council
ID : MR/R014019/1
Pays : United Kingdom
Organisme : Department of Health
ID : NIHR200153
Pays : United Kingdom
Références
J Immunol. 2018 Jan 15;200(2):375-383
pubmed: 29311378
Nature. 2017 May 25;545(7655):495-499
pubmed: 28514441
Gut. 2018 Jun;67(6):1155-1167
pubmed: 28592438
J Clin Oncol. 2020 Jan 20;38(3):193-202
pubmed: 31790344
Cell Host Microbe. 2016 Jul 13;20(1):99-106
pubmed: 27345697
Gastroenterology. 2015 Mar;148(3):590-602.e10
pubmed: 25479137
Nat Immunol. 2018 Oct;19(10):1100-1111
pubmed: 30250184
Nat Immunol. 2020 Apr;21(4):442-454
pubmed: 32152508
Gastroenterology. 2010 Oct;139(4):1246-56, 1256.e1-5
pubmed: 20558165
Intensive Care Med. 2018 Nov;44(11):1836-1848
pubmed: 30291379
J Clin Invest. 2018 Oct 1;128(10):4573-4587
pubmed: 30084841
Liver Int. 2014 Nov;34(10):1496-503
pubmed: 24606193
Front Immunol. 2018 Dec 14;9:2948
pubmed: 30619308
Gastroenterology. 2013 Jun;144(7):1426-37, 1437.e1-9
pubmed: 23474284
J Hepatol. 2018 Dec;69(6):1294-1307
pubmed: 30171870
Hepatology. 2016 Nov;64(5):1667-1682
pubmed: 27302828
Sci Immunol. 2020 Jan 3;5(43):
pubmed: 31901074
Nat Med. 2010 Apr;16(4):452-9
pubmed: 20208540
BMC Res Notes. 2014 Apr 12;7:233
pubmed: 24725742
Front Immunol. 2017 Jun 01;8:626
pubmed: 28620383
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
PLoS Biol. 2005 Apr;3(4):e113
pubmed: 15799695
Hepatology. 2015 Jul;62(1):279-91
pubmed: 25810240
J Hepatol. 2008 Nov;49(5):845-61
pubmed: 18801592
Lancet Oncol. 2018 Jul;19(7):940-952
pubmed: 29875066
Immunity. 2017 Oct 17;47(4):752-765.e5
pubmed: 29045904
Nat Immunol. 2010 Apr;11(4):295-302
pubmed: 20228796
Front Immunol. 2019 Oct 04;10:2298
pubmed: 31636634
Lancet. 2019 Sep 7;394(10201):869-881
pubmed: 31498101
Gut. 2018 Oct;67(10):1870-1880
pubmed: 28847867
J Leukoc Biol. 2016 Dec;100(6):1239-1254
pubmed: 27671246
Front Immunol. 2019 Aug 27;10:2022
pubmed: 31507611
J Immunol. 2014 Jul 1;193(1):344-53
pubmed: 24890723
Leukemia. 2017 Feb;31(2):470-478
pubmed: 27479178
Nat Rev Immunol. 2020 Apr;20(4):209-215
pubmed: 31965064
J Hepatol. 2014 Dec;61(6):1385-96
pubmed: 25135860
Hepatology. 2014 Apr;59(4):1564-76
pubmed: 24282114
J Hepatol. 2015 Apr;62(1 Suppl):S112-20
pubmed: 25920080
Gastroenterology. 2015 Mar;148(3):603-615.e14
pubmed: 25479139
EBioMedicine. 2019 Nov;49:258-268
pubmed: 31678004
Oncogenesis. 2018 May 25;7(5):41
pubmed: 29799520
Hepatology. 2013 Apr;57(4):1575-84
pubmed: 23150232
Oncotarget. 2017 May 31;8(57):97671-97682
pubmed: 29228642
Intensive Care Med Exp. 2016 Dec;4(1):22
pubmed: 27430881
Crit Care. 2019 Nov 28;23(1):384
pubmed: 31779663
Gut. 2018 Feb;67(2):333-347
pubmed: 28450389
Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6303-8
pubmed: 19332785
Hepatology. 2012 Aug;56(2):735-46
pubmed: 22334567
Sci Transl Med. 2014 May 21;6(237):237ra66
pubmed: 24848256
J Leukoc Biol. 2010 Aug;88(2):233-40
pubmed: 20483923
Gut. 2017 Mar;66(3):519-529
pubmed: 26860769
Crit Care. 2010;14(6):R220
pubmed: 21118528
Life Sci Alliance. 2019 Dec 10;3(1):
pubmed: 31822557
Nat Rev Immunol. 2018 Mar;18(3):153-167
pubmed: 28990585
Gastroenterology. 2017 Jul;153(1):263-276.e8
pubmed: 28363639
J Immunol. 2015 May 1;194(9):4545-54
pubmed: 25810391
Nat Rev Immunol. 2017 May;17(5):306-321
pubmed: 28317925
Sci Rep. 2016 Dec 07;6:38362
pubmed: 27924827